ArticleCancer management and research2025

The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study.

De Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.